DHEA induces 11β-HSD2 by acting on CCAAT/enhancer-binding proteins

Journal of the American Society of Nephrology

Volumn 19, Issue 1, 2008, Pages 92-101

  Balazs, Zoltan ^a,b   Schweizer, Roberto A S ^b   Frey, Felix J ^b   Rohner Jeanrenaud, Françoise ^c   Odermatt, Alex ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CCAAT ENHANCER BINDING PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CORTICOSTERONE; DEHYDROCORTICOSTERONE; GLUCOCORTICOID; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PRASTERONE; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CATALYSIS; CONTROLLED STUDY; CORTICOSTEROID METABOLISM; DIABETES MELLITUS; DRUG MECHANISM; ENZYME BINDING; ENZYME REGULATION; GLUCOCORTICOID METABOLISM; HORMONE PROTEIN COMPLEX; HYDROCORTISONE URINE LEVEL; HYPERTENSION; KIDNEY COLLECTING TUBULE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; TRANSCRIPTION REGULATION;

EID: 38149005365     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007030263     Document Type: Article

References (49)

1. Seckl JR, Walker BR: 11Beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: From metabolism to memory. Trends Endocrinol Metab 15: 418-424, 2004
2. Atanasov AG, Odermatt A: Readjusting the glucocorticoid balance: An opportunity for modulators of 11b-hydroxysteroid dehydrogenase type 1 activity? Endocr Metab Immune Disord Drug Targets 7: 125-140, 2007
3. Frey FJ, Odermatt A, Frey BM: Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens 13: 451-458, 2004
4. Tchernof A, Labrie F: Dehydroepiandrosterone, obesity and cardiovascular disease risk: A review of human studies. Eur J Endocrinol 151: 1-14, 2004
5. Aragno M, Cutrin JC, Mastrocola R, Perrelli MG, Restivo F, Poli G, Danni O, Boccuzzi G: Oxidative stress and kidney dysfunction due to ischemia/reperfusion in rat: Attenuation by dehydroepiandrosterone. Kidney Int 64: 836-843, 2003
6. Aragno M, Parola S, Brignardello E, Manti R, Betteto S, Tamagno E, Danni O, Boccuzzi G: Oxidative stress and eicosanoids in the kidneys of hyperglycemic rats treated with dehydroepiandrosterone. Free Radic Biol Med 31: 935-942, 2001
7. Richards RJ, Porter JR, Inserra F, Ferder LF, Stella I, Reisin E, Svec F: Effects of dehydroepiandrosterone and quinapril on nephropathy in obese Zucker rats. Kidney Int 59: 37-43, 2001
8. Pashko LL, Fairman DK, Schwartz AG: Inhibition of proteinuria development in aging Sprague-Dawley rats and C57BL/6 mice by long-term treatment with dehydroepiandrosterone. J Gerontol 41: 433-438, 1986
9. Villareal DT, Holloszy JO: Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. JAMA 292: 2243-2248, 2004
10. Frick C, Atanasov AG, Arnold P, Ozols J, Odermatt A: Appropriate function of 11beta-hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum lumen is dependent on its N-terminal region sharing similar topological determinants with 50-kDa esterase. J Biol Chem 279: 31131-31138, 2004
11. Atanasov AG, Nashev LG, Schweizer RA, Frick C, Odermatt A: Hexose-6-phosphate dehydrogenase determines the reaction direction of 11beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett 571: 129-133, 2004
12. Lavery GG, Walker EA, Draper N, Jeyasuria P, Marcos J, Shackleton CH, Parker KL, White PC, Stewart PM: Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem 281: 6546-6551, 2006
13. White PC, Mune T, Agarwal AK: 11 Beta-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18: 135-156, 1997
14. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM: 11Beta-hydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response. Endocr Rev 25: 831-866, 2004
15. Homma M, Onodera T, Hirabatake M, Oka K, Kanazawa M, Miwa T, Hayashi T: Activation of 11 beta-hydroxysteroid dehydrogenase by dehydroepiandrosterone sulphate as an anti-hypertensive agent in spontaneously hypertensive rats. J Pharm Pharmacol 50: 1139-1145, 1998
16. Arnold P, Tam S, Yan L, Baker ME, Frey FJ, Odermatt A: Glutamate115 renders specificity of human 11beta-hydroxysteroid dehydrogenase type 2 for the cofactor NAD(+). Mol Cell Endocrinol 201: 177-187, 2003
17. Apostolova G, Schweizer RA, Balazs Z, Kostadinova RM, Odermatt A: Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J Physiol Endocrinol Metab 288: E957-E964, 2005
18. Pei DQ, Shih CH: Transcriptional activation and repression by cellular DNA-binding protein C/EBP. J Virol 64: 1517-1522, 1990
19. Williams LJ, Lyons V, MacLeod I, Rajan V, Darlington GJ, Poli V, Seckl JR, Chapman KE: C/EBP regulates hepatic transcription of 11beta -hydroxysteroid dehydrogenase type 1: A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways. J Biol Chem 275: 30232-30239, 2000
20. Gout J, Tirard J, Thevenon C, Riou JP, Begeot M, Naville D: CCAAT/ enhancer-binding proteins (C/EBPs) regulate the basal and cAMP-induced transcription of the human 11beta-hydroxysteroid dehydrogenase encoding gene in adipose cells. Biochimie 88: 1115-1124, 2006
21. Djelidi S, Beggah A, Courtois-Coutry N, Fay M, Cluzeaud F, Viengchareun S, Bonvalet JP, Farman N, Blot-Chabaud M: Basolateral translocation by vasopressin of the aldosterone-induced pool of latent Na-K-ATPases is accompanied by alphal subunit dephosphorylation: Study in a new aldosterone-sensitive rat cortical collecting duct cell line. J Am Soc Nephrol 12: 1805-1818, 2001
22. Liu D, Dillon JS: Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 277: 21379-21388, 2002
23. Liu D, Si H, Reynolds KA, Zhen W, Jia Z, Dillon JS: Dehydroepiandrosterone protects vascular endothelial cells against apoptosis through a Galphai protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression. Endocrinology 148: 3068-3076, 2007
24. Buck M, Poli V, van der Geer P, Chojkier M, Hunter T: Phosphorylation of rat serine 105 or mouse threonine 217 in C/EBP beta is required for hepatocyte proliferation induced by TGF alpha. Mol Cell 4: 1087-1092, 1999
25. Muller C, Cluzeaud F, Pinon GM, Rafestin-Oblin ME, Morfin R: Dehydroepiandrosterone and its 7-hydroxylated metabolites do not interfere with the transactivation and cellular trafficking of the glucocorticoid receptor. J Steroid Biochem Mol Biol 92: 469-476, 2004
26. Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 242: 583-585, 1988
27. Atanasov AG, Ignatova ID, Nashev LG, Dick B, Ferrari P, Frey FJ and Odermatt A: Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: A novel mechanism of apparent mineralocorticoid excess. J Am Soc Nephrol 18: 1262-1270, 2007
28. Ackermann D, Vogt B, Escher G, Dick B, Reichen J, Frey BM, Frey FJ: Inhibition of 11beta-hydroxysteroid dehydrogenase by bile acids in rats with cirrhosis. Hepatology 30: 623-629, 1999
29. Vogt B, Dick B, N'Gankam V, Frey FJ, Frey BM: Reduced 11beta-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome. J Clin Endocrinol Metab 84: 811-814, 1999
30. Quattropani C, Vogt B, Odermatt A, Dick B, Frey BM, Frey FJ: Reduced activity of 11beta-hydroxysteroid dehydrogenase in patients with cholestasis. J Clin Invest 108: 1299-1305, 2001
31. Stauffer AT, Rochat MK, Dick B, Frey FJ, Odermatt A: Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem 277: 26286-26292, 2002
32. Thiesson HC, Jensen BL, Bistrup C, Ottosen PD, McNeilly AD, Andrew R, Seckl J, Skott O: Renal sodium retention in cirrhotic rats depends on glucocorticoid-mediated activation of mineralocorticoid receptor due to decreased renal 11beta-HSD-2 activity. Am J Physiol Regul Integr Comp Physiol 292: R625-R636, 2007
33. Lovati E, Ferrari P, Dick B, Jostarndt K, Frey BM, Frey FJ, Schorr U, Sharma AM: Molecular basis of human salt sensitivity: The role of the 11beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 84: 3745-3749, 1999
34. Fagerudd JA, Tarnow L, Jacobsen P, Stenman S, Nielsen FS, Pettersson-Fernholm KJ, Gronhagen-Riska C, Parving HH, Groop PH: Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes 47: 439-444, 1998
35. Strojek K, Grzeszczak W, Morawin E, Adamski M, Lacka B, Rudzki H, Schmidt S, Keller C, Ritz E: Nephropathy of type II diabetes: Evidence for hereditary factors? Kidney Int 51: 1602-1607, 1997
36. Lavery GG, McTernan CL, Bain SC, Chowdhury TA, Hewison M, Stewart PM: Association studies between the HSD11B2 gene (encoding human 11beta-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathy. Eur J Endocrinol 146: 553-558, 2002
37. Brereton PS, van Driel RR, Suhaimi F, Koyama K, Dilley R, Krozowski Z: Light and electron microscopy localization of the 11beta-hydroxysteroid dehydrogenase type I enzyme in the rat. Endocrinology 142: 1644-1651, 2001
38. Trautwein C, Caelles C, van der Geer P, Hunter T, Karin M, Chojkier M: Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain. Nature 364: 544-547, 1993
39. Lee SJ, Kim SG: Role of p90 ribosomal S6-kinase-1 in oltipraz-induced specific phosphorylation of CCAAT/enhancer binding protein-beta for GSTA2 gene transactivation. Mol Pharmacol 69: 385-396, 2006
40. Escher G, Galli I, Vishwanath BS, Frey BM, Frey FJ: Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle. J Exp Med 186: 189-198, 1997
41. Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M, Stewart PM: Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 16: 1037-1044, 2001
42. Kostadinova RM, Nawrocki AR, Frey FJ, Frey BM: Tumor necrosis factor alpha and phorbol 12-myristate-13-acetate down-regulate human 11beta-hydroxysteroid dehydrogenase type 2 through p50/ p50 NF-kappaB homodimers and Egr-1. FASEB J 19: 650-652, 2005
43. Kimura M, Tanaka S, Yamada Y, Kiuchi Y, Yamakawa T, Sekihara H: Dehydroepiandrosterone decreases serum tumor necrosis factor-alpha and restores insulin sensitivity: Independent effect from secondary weight reduction in genetically obese Zucker fatty rats. Endocrinology 139: 3249-3253, 1998
44. Miller M, Shuman JD, Sebastian T, Dauter Z, Johnson PF: Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein alpha. J Biol Chem 278: 15178-15184, 2003
45. Audige A, Dick B, Frey BM, Frey FJ, Corman B, Vogt B: Glucocorticoids and 11 beta-hydroxysteroid dehydrogenase type 2 gene expression in the aging kidney. Eur J Clin Invest 32: 411-420, 2002
46. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001
47. Schweizer RA, Zurcher M, Balazs Z, Dick B, Odermatt A: Rapid hepatic metabolism of 7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1: Species-specific differences between the rat, human, and hamster enzyme. J Biol Chem 279: 18415-18424, 2004
48. Atanasov AG, Nashev LG, Tarn S, Baker ME, Odermatt A: Organotins disrupt the 11beta-hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids. Environ Health Perspect 113: 1600-1606, 2005
49. Schweizer RA, Atanasov AG, Frey BM, Odermatt A: A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): Flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol Cell Endocrinol 212: 41-49, 2003